肥胖产妇剖宫产术后预防性口服头孢氨苄和甲硝唑与安慰剂比较减少感染并发症的随机对照试验
这项随机双盲试验在肥胖且胎膜破裂≥4小时的剖宫产产妇中,比较术后48小时口服头孢氨苄和甲硝唑与安慰剂的感染复合结局。共随机321人,头孢氨苄-甲硝唑组复合感染发生率5.6%,安慰剂组6.8%,差异无统计学意义(OR 0.81,95%CI 0.33-2.02,P=.64)。
要点
- 肥胖产妇剖宫产术后口服头孢氨苄和甲硝唑48小时未显著降低30天内感染并发症。
- 头孢氨苄-甲硝唑组感染复合结局5.6%,安慰剂组6.8%,差异1.2%(95%CI -2.5%至5.0%)。
- 两组均未报告严重不良事件,包括过敏反应。
核心结论
- 在术前接受包含阿奇霉素的广谱抗生素方案的肥胖剖宫产产妇中,术后加用48小时口服头孢氨苄和甲硝唑未显著降低分娩后30天内感染并发症发生率。
研究设计与样本
- 随机双盲临床试验,2017年8月至2023年8月在两个医疗中心开展。
- 纳入妊娠BMI≥30且胎膜破裂≥4小时、接受剖宫产并术前静脉注射头孢唑林和阿奇霉素标准预防的产妇。
- 参与者随机接受口服头孢氨苄500 mg和甲硝唑500 mg或相同安慰剂,每8小时一次,术后连用48小时。
- 计划样本量302例,以检测主要结局从安慰剂组25%降至抗生素组12.5%,实际随机321例(平均年龄27.5±6.1岁,平均BMI 38.4±6.8),头孢氨苄-甲硝唑组160例,安慰剂组161例,284例(88.5%)按方案完成研究。
主要发现
- 总体感染复合结局发生率为6.2%(95%CI 3.8-9.5%)。
- 头孢氨苄-甲硝唑组9例(5.6%)发生复合感染结局,安慰剂组11例(6.8%),差异1.2%(95%CI -2.5%至5.0%),OR 0.81(95%CI 0.33-2.02),P=.64。
- 两组均未报告严重不良事件,包括过敏反应。
关键数值与推荐
- 主要结局为剖宫产术后30天内感染并发症复合结局,包括子宫内膜炎、手术部位感染或其他剖宫产后感染(盆腔脓毒性血栓、基于影像学诊断的腹腔或盆腔脓肿)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare prophylactic oral cephalexin and metronidazole with placebo for 48 hours after cesarean delivery following membrane rupture on the frequency of composite infection morbidity postpartum among pregnant individuals with obesity. METHODS: This randomized, double-blind clinical trial was conducted at two medical centers from August 2017 to August 2023. We enrolled women with obesity (pregnancy body mass index [BMI] 30 or higher) and ruptured membranes (for 4 hours or more) undergoing cesarean delivery who were also receiving standard intravenous preoperative prophylaxis with cefazolin and azithromycin. Participants were assigned randomly to receive either oral cephalexin (500 mg) and metronidazole (500 mg) or an identical placebo every 8 hours for 48 hours after their cesarean delivery. The primary outcome was a composite of infection complications , defined as a composite of endometritis, surgical site infection, or other postcesarean infections (pelvic septic thrombosis, abdominal or pelvic abscess based on radiologic diagnosis) within 30 days after cesarean delivery. With an anticipated relative risk reduction of 50% and a two-sided α=.05 with 80% power and a 1:1 ratio of exposed to unexposed, a total sample size of 302 participants was planned to detect a reduction in the primary outcome from 25% in the placebo group to 12.5% in the antibiotic group. RESULTS: Of the 321 women who were randomized (mean±SD age 27.5±6.1 years, mean±SD BMI 38.4±6.8), 160 received cephalexin-metronidazole and 161 received placebo with a total of 284 (88.5%) who completed the study per protocol. The overall rate of the composite infection outcome was 6.2% (95% CI, 3.8-9.5%). In the cephalexin-metronidazole group, 9 women (5.6%) developed the composite compared with 11 women (6.8%) in the placebo group (difference 1.2%, 95% CI, -2.5% to 5.0%; odds ratio 0.81, 95% CI, 0.33-2.02; P =.64). No serious adverse events, including allergic reactions, were reported in either group. CONCLUSION: In women with obesity undergoing cesarean delivery with an extended-spectrum preoperative antibiotic regimen that included azithromycin, the addition of a postoperative 48-hour course of oral cephalexin and metronidazole did not significantly lower the rate of infection complications within 30 days after delivery. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT03187106.
引用
- Saad AF, Goldman B, Spencer N, et al. Prophylactic Oral Cephalexin and Metronidazole Compared With Placebo After Cesarean Delivery to Reduce Infection Complications in Women With Obesity: A Randomized Controlled Trial. Obstet Gynecol. 2025. PMID: 40403315. doi:10.1097/AOG.0000000000005936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。